For the first time, most Americans using GLP-1 drugs say they take them to lose weight, not to treat diabetes.
At a Glance
- EY-Parthenon reports 54% of U.S. GLP-1 users now take them for weight management.
- This marks a mainstream shift in why people start and stay on these medicines.
- The finding rests on large consumer surveys, not small samples.
- Rising weight-loss use is already changing how people shop and eat.
Weight Loss Now Leads GLP-1 Use
EY-Parthenon says weight-management users now make up the majority, at 54% of U.S. GLP-1 users, surpassing those who use the drugs for diabetes or other health reasons. This point matters because it signals a change in how patients and doctors view these drugs. They are moving from a diabetes-first medicine to a broader tool for obesity care. That shift reshapes demand, coverage debates, and the kinds of support users seek from doctors, pharmacies, and insurers.
EY-Parthenon ties this shift to consumer behavior in daily life. People on GLP-1 medicines report different grocery carts, fewer impulse snacks, and new spending on smaller sizes and fitness gear, according to coverage of the research. These are not fringe ripples. When millions make small changes, food makers, retailers, and clothing brands feel it. That feedback loop can reinforce the move to weight-loss use, as users see visible results in both health and lifestyle.
How The Survey Grounded The Finding
EY-Parthenon points to a broad consumer study behind the headline result, which included large samples of current and former GLP-1 users alongside the general public. The scale matters because it reduces the odds that a narrow group, like early adopters from one region, skews the picture. While different studies count “current,” “former,” or “ever” users in different ways, this work focused on the core question: why are people taking these drugs right now.
Other surveys and trackers show GLP-1 use rising over the last few years. Estimates of total adoption vary by method, but the trend line rises across sources, and that helps explain how weight-loss use could pass diabetes use at scale. News coverage of the EY-Parthenon work underscores this tipping point and shows how it influences shopping and health routines across age and income groups.
Why This Shift Changes Markets And Medicine
Food and beverage companies are already modeling lower demand for high-calorie items as GLP-1 users report eating less and choosing more protein and fewer sweets. Retailers are rethinking sizes, returns, and loyalty programs as waistlines change and shoppers churn through wardrobes faster. The impact will not hit only snacks and soda. Restaurant traffic, alcohol sales, and even travel services can feel a nudge when millions change portion sizes and daily habits.
Per a new EY-Parthenon survey, 54% of US GLP-1 users now take it mainly for weight loss, the first time that's been the majority. 61% say they eat more protein. Good. If you're on one, stay doctor-supervised, eat your protein, and lift, or you lose muscle you'll want back at 50
— Cross And Crowbar (@CrossAndCrowbar) October 23, 2026
Health systems and insurers now face a practical question: how to design coverage, coaching, and follow-up for weight loss as a primary goal. That includes nutrition support, strength training to protect muscle, and plans for people cycling on and off the drugs. A weight-first lens also affects how primary care doctors triage risk for sleep apnea, fatty liver, and heart disease. Patients often have overlapping issues, so care teams need clear goals and realistic timelines.
What To Watch Next
Expect more employers and insurers to test coverage rules that reward measured, lasting weight loss while watching costs. Expect more food brands to roll out high-protein, lower-sugar options that pair with smaller appetites. Expect more clinics to bundle prescriptions with coaching, resistance training, and meal plans. These are not fads. They are practical moves that follow the money and the data. When most users take GLP-1 drugs for weight goals, the market meets them there.
Sources:
cbsnews.com, ey.com, foodinstitute.com
